Lexaria Bioscience : Corporate Highlight Sheet

LEXARIA BIOSCIENCE CORP.

NASDAQ: LEXX

INVESTOR CONTACT

Phone: [phone] ext. 202 [e-mail]

DRUG DELIVERY PLATFORM INNOVATOR

Lexaria Bioscience Corp's. (Nasdaq: LEXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients ("APIs") enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. The Company's technology can be applied to many different ingestible product formats, including, oral suspensions, tablets, capsules, and more. DehydraTECH has repeatedly demonstrated with cannabinoids and nicotine the ability to increase bio-absorptionby up to 5-10x,reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also planned for evaluation for anti-virals, vitamins, non-steroidalanti-inflammatory drugs (NSAIDs), and more. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patent applications pending around the world. For more information, please visit www.lexariabioscience.com.

Investment Highlights

• Disruptive, patented technology - fast acting, less expensive and more effective oral drug delivery with multiple opportunities for success in oral cannabinoids, antivirals, oral nicotine, and other active pharmaceutical ingredients
• Lexaria's wholly owned revenue generating subsidiary Lexaria Hemp Corp. generates revenues from DehydraTECH CBD powders and has received verbal orders from existing licensees to produce at least 56 million servings in 2021
• Up list to Nasdaq Capital Markets and a US$11 million financing completed in January 2021
• Additional DehydraTECH transactions expected through 2021

DehydraTECH™

• Patented formulation and dehydration processing method changes how the body detects and absorbs drugs orally
• 21 patents granted (>50 pending) covering method-of-use,composition-of-matter and medical treatment claims

Speeds up onset

Increases bioavailability

Improves drug potency

Lower dosage

Lower cost

Patented DehydraTECH™ Process

1	Combine Active	2	Apply to food / carrier	3 Perform dehydration	4	Render as powder or liquid for use
	Pharmaceutical Ingredient		particles	synthesis procedure		in desired final form factor

with Fatty Acid Oil

Recent Highlights

•

•

•

Successful results from our 2021 independent third-party laboratory studies, HYPER-A21-1: up to 2,178% more CBD delivered

into bloodstream, up to 1,737% more CBD delivered into brain tissue and HYPER-A21-2: new formulation delivers up to 2,708% more CBD into bloodstream

Successful results from our 2021 independent third-partyhuman clinical study, HYPER-H21-1: demonstrating that DehydraTECH lowers blood pressure and delivers superior performance over generic CBD controls

Successful results from third-party laboratory studies, VIRAL-C21-3,VIRAL-A20-2 and VIRAL-A20-3:DehydraTECH-enabled drugs effectively inhibit the COVID-19/SARS-CoV-2virus and deliver two to three-foldincrease in oral delivery of antiviral drugs

PRICE	52 WK RANGE	AVG. VOLUME	SHARES OUTSTANDING	MARKET CAP	INSIDER OWNERSHIP
$6.41	$3.98-$12.50	1,375,330	5.7 M	$36.7 M USD	10%

Lexaria Bioscience Corp. - #100-740 McCurdy Road - Kelowna, BC, Canada

www.lexariabioscience.com

LEXARIA BIOSCIENCE CORP.

NASDAQ: LEXX

INVESTOR CONTACT

Phone: [phone] ext. 202 [e-mail]

DRUG DELIVERY PLATFORM INNOVATOR

Additional 2021 DehydraTECH Investigations Cumulative Market Value Over $100 Billion

Planned pharmacokinetic ("PK") studies will evaluate DehydraTECH's ability to improve quantity of drug delivered and speed with which it is delivered, in all of these areas:

• Oral Cannabinoids: Estimated at $18.4 billion in 2021 and expected to reach $46.2 billion in 2025
• Antivirals: Estimated at $52.1 billion in 2021 and expected to grow to $66.7 billion by 2025
• Oral Mucosal Nicotine: Global smokeless tobacco products was a $13.6 billion market in 2018, forecast to grow at 7.2% per year until 2025
• PDE5 Inhibitors: Phosphodiesterase inhibitors with brand names such as Viagra represented a $4.4 billion market in 2014.
• Human Hormones: Estrogen and Testosterone replacement therapies represent a $21.9 billion market
• Ibuprofen and Naproxen: Global NSAID sales were $15.6 billion in 2019 and projected $24.4 billion by 2027
• Vitamin D3: Global Vitamin D3 market size was $1.1 billion in 2021, growing at 7.0% per year and expected to reach $1.7 billion in 2026

Lexaria Nicotine LLC (Majority-Owned)

• Altria Group international license rights for undisclosed royalty
• Research and Development agreement with British American Tobacco

+

Majority Interest

Minority Interest

Lexaria Pharmaceutical Corp. (Wholly-Owned)

• Programs commenced to prove delivery effectiveness in antiviral therapies for COVID-19/SARS-CoV-2 and other infectious diseases such as HIV, HSV, Influenza, EBV, HEP, CMV

Lexaria Hemp Corp. (Wholly-Owned)

• Clinically proven to increase rate and extent of orally ingested CBD (https://www.ncbi.nlm.nih.gov/pubmed/31512143)
• Established North American partnerships generating revenues from DehydraTECH technology

MANAGEMENT

Chris Bunka, Chairman & CEO

• Launched several successful private and public companies since the late 1980's
• Extensive experience in the capital markets, corporate governance, M&A and finance
• Named inventor on multiple patent innovations

John Docherty, M.Sc., President & Director

• Specialist in development of drug delivery technologies
• Former President and COO of Helix BioPharma Corp. (TSX: HBP)
• Named inventor on multiple issued and pending patents
• Pharmacologist and toxicologist

Disclaimer: This fact sheet includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, evaluation of medical marijuana projects, alternative health projects or products, and cannabidiol-fortified products or services for participation and/or financing, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements including, without limitation, foreign exchange and other financial markets; changes of the interest rates on borrowings; whether or not the Company will be successful in executing its business plan in whole or in part; hedging activities; changes in commodity prices; changes in the marketing or capital project expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Lexaria Corp. operates. These and other risks and uncertainties are more fully described in our periodic reports and other disclosure documents filed by Lexaria Corp. from time to time with regulatory authorities available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov, and the reader is encouraged to review these documents. Planned dates stated herein are estimates only, based on best information available. Dates are not assured and are subject to revision without notice. The Company assumes no obligation, except as required by law, to update any forward-looking statement, whether as a result of new information, future events or otherwise. This fact sheet is not an offer to sell or a solicitation of an offer to buy securities of Lexaria Bioscience Corp. It is a short summary of certain information for introductory purposes only and is not to be relied upon for investment purposes. No statement within has been evaluated by the Food and Drug Administration, and no product or service is intended to diagnose, treat, cure or prevent any disease. All supporting information for this fact sheet can be found at www.lexariabioscience.com.

Lexaria Bioscience Corp. - #100-740 McCurdy Road - Kelowna, BC, Canada

www.lexariabioscience.com